Drug Profile
Cord blood stem cell therapy - Translational Biosciences
Alternative Names: human UC-MSC - Translational Biosciences; Human umbilical cord tissue-derived mesenchymal stem cells; huMSC - Translational Biosciences; UC-MSC -Translational Biosciences; Umbilical cord mesenchymal stem cells - Translational BiosciencesLatest Information Update: 11 May 2017
Price :
$50
*
At a glance
- Originator Translational Biosciences
- Class Mesenchymal stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Osteoarthritis; Rheumatoid arthritis
Most Recent Events
- 26 Apr 2017 Translational Biosciences withdraws a phase-I/II clinical trial in Osteoarthritis prior to enrolment due to no enrolment in Panama (Intra-articular) (IV) (NCT02237846)
- 13 Dec 2016 Phase-I/II development is ongoing in Panama
- 01 Sep 2014 Phase-I/II clinical trials in Osteoarthritis of the knee in Panama (Intra-articular & IV)